Apimeds Pharmaceuticals US (APUS) Interest Coverage Ratio (2024 - 2026)
Apimeds Pharmaceuticals US's (APUS) quarterly Interest Coverage Ratio came in at 1.95 in Q2 2026, up 98.31% on a YoY basis from 0.98 in Q2 2025, and up 94.03% quarter-over-quarter from 32.65 in Q4 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Interest Coverage Ratio (2024 - 2026) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Interest Coverage Ratio for 3 consecutive years, with 1.95 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest Coverage Ratio rose 98.31% year-over-year to 1.95; the trailing twelve-month figure through Jun 2026 stood at 5.14 (up 81.49% YoY), and the FY2025 full-year result was 42.09, down 288.6% from the prior year.
- Interest Coverage Ratio advanced to 1.95 in Q2 2026 per APUS's latest filing, from 32.65 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 1.95 in Q2 2026 and bottomed at 292.69 in Q3 2025.
- Historically, Interest Coverage Ratio has averaged 55.41 across 3 years, with a median of 10.1 in 2024.
- The sharpest annual moves came in 2025 and 2026: Interest Coverage Ratio tumbled 3084.28% in 2025, then jumped 98.31% in 2026.
- Over 3 years, Interest Coverage Ratio stood at 7.65 in 2024, then tumbled by 327.06% to 32.65 in 2025, then surged by 94.03% to 1.95 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1.95, 32.65, and 292.69 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Apimeds Pharmaceuticals US | 3.79 Mn | 3.79 Mn | - | -1.95 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.95 |
| Dec 31, 2025 | -32.65 |
| Sep 30, 2025 | -292.69 |
| Jun 30, 2025 | -115.55 |
| Mar 31, 2025 | -9.58 |
| Dec 31, 2024 | -7.65 |
| Sep 30, 2024 | -9.19 |
| Jun 30, 2024 | -19.34 |
| Mar 31, 2024 | -10.10 |